Axcan Pharma Holding B.V. and Eurand N.V. have renamed of their combined companies to Aptalis Pharma. The two companies are working to develop therapies to treat cystic fibrosis and gastrointestinal disorders. Axcan completed its acquisition of Eurand N.V. in February 2011.

Aptalis Pharmaceutical Technologies, formerly known as Eurand Pharmaceutical Technologies, will continue to develop and manufacture products, as well as support the drug development efforts for Aptalis Pharma’s pipeline of products.

Aptalis has a portfolio of oral drug delivery technology platforms including customized drug release, bioavailability enhancement, and taste masking. Aptalis Pharma can now provide licensing, manufacturing, and R&D capabilities for customized drug formulation solutions across a range of dosage forms and therapies.